HK1138321A1 - Method for activation of helper cell and composition for use in he method - Google Patents

Method for activation of helper cell and composition for use in he method

Info

Publication number
HK1138321A1
HK1138321A1 HK10104389.9A HK10104389A HK1138321A1 HK 1138321 A1 HK1138321 A1 HK 1138321A1 HK 10104389 A HK10104389 A HK 10104389A HK 1138321 A1 HK1138321 A1 HK 1138321A1
Authority
HK
Hong Kong
Prior art keywords
activation
composition
helper cell
helper
cell
Prior art date
Application number
HK10104389.9A
Other languages
English (en)
Chinese (zh)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of HK1138321A1 publication Critical patent/HK1138321A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
HK10104389.9A 2007-02-27 2010-05-04 Method for activation of helper cell and composition for use in he method HK1138321A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007047317 2007-02-27
PCT/JP2008/053417 WO2008105462A1 (ja) 2007-02-27 2008-02-27 ヘルパーｔ細胞の活性化方法およびそのための組成物

Publications (1)

Publication Number Publication Date
HK1138321A1 true HK1138321A1 (en) 2010-08-20

Family

ID=39721287

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10104389.9A HK1138321A1 (en) 2007-02-27 2010-05-04 Method for activation of helper cell and composition for use in he method

Country Status (26)

Country Link
US (2) US10139395B2 (sl)
EP (1) EP2119778B1 (sl)
JP (2) JP5225262B2 (sl)
KR (1) KR101598228B1 (sl)
CN (6) CN103149366B (sl)
AU (1) AU2008220031B2 (sl)
BR (1) BRPI0808084A2 (sl)
CA (1) CA2677075C (sl)
CY (1) CY1117150T1 (sl)
DK (1) DK2119778T3 (sl)
ES (1) ES2559062T3 (sl)
HK (1) HK1138321A1 (sl)
HR (1) HRP20160020T1 (sl)
HU (1) HUE027472T2 (sl)
IL (1) IL200161A (sl)
MX (2) MX2009009168A (sl)
MY (2) MY164867A (sl)
NZ (3) NZ599161A (sl)
PL (1) PL2119778T3 (sl)
PT (1) PT2119778E (sl)
RU (2) RU2009135802A (sl)
SG (1) SG177998A1 (sl)
SI (1) SI2119778T1 (sl)
UA (1) UA101608C2 (sl)
WO (1) WO2008105462A1 (sl)
ZA (1) ZA200905467B (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
AU2008220031B2 (en) 2007-02-27 2013-06-13 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
CN102762719A (zh) 2009-12-08 2012-10-31 威尔森沃尔夫制造公司 用于过继细胞疗法的细胞培养的改进方法
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
AU2011313327B2 (en) * 2010-10-05 2015-10-22 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
BR112014002747A2 (pt) 2011-09-14 2020-10-27 International Institute Of Cancer Immunology, Inc método para medir um anticorpo anti-wt1
JP6218175B2 (ja) * 2011-12-14 2017-10-25 国立大学法人高知大学 ヘルパーｔ細胞誘導性ポリペプチドの改変
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
CN104797711B (zh) * 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
SG10201705028WA (en) 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
EP3769782A1 (en) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP3112378B1 (en) * 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
JP6770269B2 (ja) 2015-06-25 2020-10-14 国立大学法人神戸大学 経口腫瘍ワクチン
EP3560513A4 (en) 2016-12-26 2020-10-14 National University Corporation Kobe University ANTICANCER THERAPY USING A COMBINATION OF AN ORAL TUMOR VACCINE AND AN IMMUNOSUPPRESSION INHIBITOR
CN116134131A (zh) 2019-12-31 2023-05-16 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
WO2000006602A1 (fr) 1998-07-31 2000-02-10 Haruo Sugiyama Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1
IL142216A0 (en) 1998-09-30 2002-03-10 Corixa Corp A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
BRPI0208183B8 (pt) * 2001-03-22 2021-05-25 Sugiyama Haruo peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
EP2014300B1 (en) 2001-06-29 2011-01-12 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprising a cancer antigen based on the product of a tumor suppressor gene WT1 and a cationic liposome
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
AU2003242305A1 (en) 2002-06-12 2003-12-31 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptide
EP1550453B1 (en) 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Cancer antigen peptide preparation
WO2004026897A1 (ja) 2002-09-20 2004-04-01 Chugai Seiyaku Kabushiki Kaisha Ｗｔ１置換型ペプチド
AU2004204031B2 (en) 2003-01-15 2010-03-04 International Institute Of Cancer Immunology, Inc. Dimerized peptide
KR101292971B1 (ko) 2003-06-27 2013-08-12 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
AU2004294345B2 (en) * 2003-12-01 2012-02-23 Sloan-Kettering Institute For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
WO2005095598A1 (ja) 2004-03-31 2005-10-13 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来の癌抗原ペプチド
JP4719876B2 (ja) * 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
AU2006319892B2 (en) 2005-11-30 2012-05-10 International Institute Of Cancer Immunology, Inc. Novel peptide compound
DK1988163T3 (da) 2006-02-22 2012-08-20 Int Inst Cancer Immunology Inc Hla-a*3303-begrænset wt1 peptid og farmaceutisk sammensætning omfattende det samme
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
ES2629578T3 (es) 2006-12-28 2017-08-11 International Institute Of Cancer Immunology, Inc. Péptido WT1 restringido a HLA-A*1101 y una composición farmacéutica que comprenden el mismo
AU2008220031B2 (en) 2007-02-27 2013-06-13 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
MX343633B (es) 2007-03-05 2016-11-11 Int Inst Cancer Immunology Inc Gen receptor de celulas t especificas de antigeno cancerigeno, peptido codificado por el gen, y uso de los mismos.
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
AU2011313327B2 (en) 2010-10-05 2015-10-22 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
SG10201705028WA (en) 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell

Also Published As

Publication number Publication date
SI2119778T1 (sl) 2016-03-31
US20200064332A1 (en) 2020-02-27
MX2009009168A (es) 2009-09-07
UA101608C2 (uk) 2013-04-25
EP2119778B1 (en) 2015-11-04
US20100247556A1 (en) 2010-09-30
NZ599160A (en) 2012-07-27
NZ578721A (en) 2012-04-27
EP2119778A1 (en) 2009-11-18
JP5225262B2 (ja) 2013-07-03
ZA200905467B (en) 2010-05-26
WO2008105462A1 (ja) 2008-09-04
CN104774910B (zh) 2018-04-10
CY1117150T1 (el) 2017-04-05
US11555814B2 (en) 2023-01-17
PT2119778E (pt) 2016-02-15
HUE027472T2 (en) 2016-09-28
RU2680539C2 (ru) 2019-02-22
DK2119778T3 (en) 2016-01-25
JP2013139448A (ja) 2013-07-18
CA2677075C (en) 2018-07-10
CN103088103A (zh) 2013-05-08
CN104312974A (zh) 2015-01-28
EP2119778A4 (en) 2010-08-18
CN104774910A (zh) 2015-07-15
MY164867A (en) 2018-01-30
RU2014104572A (ru) 2015-08-20
CN104312974B (zh) 2018-09-04
SG177998A1 (en) 2012-02-28
CN103103246B (zh) 2018-05-01
ES2559062T3 (es) 2016-02-10
PL2119778T3 (pl) 2016-04-29
MX352947B (es) 2017-12-14
MY158219A (en) 2016-09-15
KR20090125067A (ko) 2009-12-03
RU2009135802A (ru) 2011-04-10
AU2008220031A1 (en) 2008-09-04
JP5714619B2 (ja) 2015-05-07
NZ599161A (en) 2012-07-27
HRP20160020T1 (hr) 2016-02-12
CN101622344A (zh) 2010-01-06
IL200161A0 (en) 2011-08-01
AU2008220031B2 (en) 2013-06-13
US10139395B2 (en) 2018-11-27
IL200161A (en) 2015-11-30
KR101598228B1 (ko) 2016-02-26
CN103149366A (zh) 2013-06-12
CN103103246A (zh) 2013-05-15
CN103088103B (zh) 2015-09-30
BRPI0808084A2 (pt) 2014-07-22
JPWO2008105462A1 (ja) 2010-06-03
CA2677075A1 (en) 2008-09-04
CN103149366B (zh) 2018-06-15

Similar Documents

Publication Publication Date Title
HK1138321A1 (en) Method for activation of helper cell and composition for use in he method
GB2443823B (en) Devices and methods for use in construction
IL202329A0 (en) Methods and compositions for stimulating cells
HK1147254A1 (en) 5-anilinoimidazopyridines and methods of use 5-
EP1984015A4 (en) METHOD AND COMPOSITIONS FOR TREATING ASTHMA IN HUMANS AND OTHER PRIMATES
EP2308884A4 (en) PROCESS FOR THE PREPARATION OF HETEROSUBSTITUTED ALKYLHALOHYDROSILANE AND ITS USE
IL206125A0 (en) Azaindolizines and methods of use
GB0709781D0 (en) Composition and method
EP2183326A4 (en) INK COMPOSITION AND METHOD OF USING THE SAME
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
GB2442084B (en) Flow-through cell and method of use
EP2308960A4 (en) Cell adhesion promoting agent and method for promoting cellular adhesion
IL192564A0 (en) Composition and method of use thereof
GB0620930D0 (en) Composition and method for use thereof
ZA201004894B (en) Nuctraceutical composition and methods of use
GB0718821D0 (en) Cement spacer for use in prosthetic cup and method of use therein
EP2115127A4 (en) METHOD AND COMPOSITIONS FOR IMPROVING CELL HEALTH IN CULTURES
ZA201004893B (en) Nuctraceutical composition and methods of use
ZA201008261B (en) Non-hydrating plaster composition and method
MY152929A (en) Polishing composition and polishing method
AU2008900868A0 (en) Improvements in or Relating to Electropolishing Apparatus and Method of Use
GB0820804D0 (en) Perinropril composition and method of use thereof
TWI365216B (en) Polishing composition for polishing lithium aluminate and method of using the same
GB0624232D0 (en) Carrying means and method of use thereof
GB0722751D0 (en) Use of gum arabic in therapy